0001179110-18-006820.txt : 20180515 0001179110-18-006820.hdr.sgml : 20180515 20180515183205 ACCESSION NUMBER: 0001179110-18-006820 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180511 FILED AS OF DATE: 20180515 DATE AS OF CHANGE: 20180515 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Luehrs Bruce CENTRAL INDEX KEY: 0001352929 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37888 FILM NUMBER: 18838272 MAIL ADDRESS: STREET 1: 8270 GREENSBORO DRIVE STREET 2: SUITE 850 CITY: MCLEAN STATE: VA ZIP: 22102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tabula Rasa HealthCare, Inc. CENTRAL INDEX KEY: 0001651561 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 465726437 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 228 STRAWBRIDGE DRIVE STREET 2: SUITE 100 CITY: MOORESTOWN STATE: NJ ZIP: 08057 BUSINESS PHONE: 866-648-2767 MAIL ADDRESS: STREET 1: 228 STRAWBRIDGE DRIVE STREET 2: SUITE 100 CITY: MOORESTOWN STATE: NJ ZIP: 08057 4 1 edgar.xml FORM 4 - X0306 4 2018-05-11 0 0001651561 Tabula Rasa HealthCare, Inc. TRHC 0001352929 Luehrs Bruce 4801 S. BROAD ST. SUITE 400 PHILADELPHIA PA 19112 1 0 0 0 Common Stock 8161 D Common Stock 2018-05-11 4 S 0 22999 46.97 D 162843 I See footnotes Common Stock 2018-05-14 4 S 0 400 46.69 D 162443 I See footnotes Common Stock 2018-05-14 4 S 0 8685 47.63 D 153758 I See footnotes Common Stock 2018-05-14 4 S 0 7916 48.29 D 145842 I See footnotes Common Stock 2018-05-15 4 S 0 1231 47.75 D 144611 I See footnotes Common Stock 2018-05-15 4 S 0 14172 48.72 D 130439 I See footnotes Common Stock 2018-05-15 4 S 0 12166 49.22 D 118273 I See footnotes Includes a restricted stock award of 3,710 shares of the Company's common stock received by Bruce Luehrs on September 28, 2016, of which shares 1,236 are vested and 2,474 are unvested. Also includes a restricted stock award of 1,855 shares of the Company's common stock received by Bruce Luehrs on September 28, 2016, all of which are vested. Also includes a restricted stock award of 2,596 shares of the Company's common stock received by Bruce Luehrs on June 16, 2017. Such common stock vests in full on the earlier of the next annual shareholder meeting or the one year anniversary of the date of grant. These securities are held by Emerald Stage2Ventures, L.P. Stage2 Capital Ventures Associates, L.P. is the general partner of Emerald Stage2 Ventures, L.P. and Stage2 Capital Associates G.P., LLC is the general partner of Stage2 Capital Ventures Associates, L.P. Bruce Luehrs, who serves as a director of the Issuer, is an officer of Stage2 Capital Associates G.P., LLC. The Reporting Person disclaims beneficial ownership (as defined in Rule 16a-1(a)(2)) of the securities reported herein (except to the extent of his pecuniary interest in such securities), and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $46.50 to $47.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $46.62 to $46.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $47.15 to $47.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $48.00 to $48.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (7) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $47.63 to $47.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (8) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $48.08 to $48.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (9) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $49.00 to $49.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (10) to this Form 4. /s/ Brian W. Adams, as attorney-in-fact for Reporting Person 2018-05-15